ArticleJournal of patient-reported outcomes2017
Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension.
Article in Journal of patient-reported outcomes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06501274 (A Pragmatic Interventional Study to Assess the Clinical Value of Capsule Sponge in the Assessment of Response to Treatment of Non-stenotic Eosinophilic Oesophagitis in a Single District General Hospital), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pragmatic Interventional Study to Assess the Clinical Value of Capsule Sponge in the Assessment of Response to Treatment of Non-stenotic Eosinophilic Oesophagitis in a Single District General Hospital
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Meta-Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials.Alimentary pharmacology & therapeutics · 2025Pooled it
- Effect of Budesonide Oral Suspension on Time to First Dysphagia Symptom Response and Dysphagia Symptom Resolution Outcomes in Patients With Eosinophilic Esophagitis.Journal of gastroenterology and hepatology · 2026Trial
- Trial
- Validation of the novel Eosinophilic Esophagitis Impact Questionnaire.Journal of patient-reported outcomes · 2023Trial
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.The World Allergy Organization journal · 2026Review
- Maintenance therapy with once or twice daily budesonide orodispersible tablets after budesonide viscous solution in eosinophilic esophagitis.Therapeutic advances in gastroenterology · 2026Article
- Validation of the novel Eosinophilic Esophagitis Symptom Questionnaire.The journal of allergy and clinical immunology. Global · 2025Article
- Patient-Reported Outcome Measures in Benign Esophageal Disorders.The American journal of gastroenterology · 2025Review
- Dupilumab Improves Histopathologic Features in Patients With Eosinophilic Esophagitis: LIBERTY EoE TREET Study Results.Gastro hep advances · 2025Article
- Assessment of real-world disease severity in patients with eosinophilic esophagitis in the United States.Therapeutic advances in gastroenterology · 2025Article
- Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.The journal of allergy and clinical immunology. Global · 2024Article
- Observational
- The Dual Lens of Endoscopy and Histology in the Diagnosis and Management of Eosinophilic Gastrointestinal Disorders-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Dysphagia, health-related quality of life, and return to work after occipitocervical fixation.Acta neurochirurgica · 2024Article
- Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2024Review
- Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis.Therapeutic advances in gastroenterology · 2024Article
- Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes.ImmunoTargets and therapy · 2024Review
- Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis.Biomedicines · 2023Review
- Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies.Current gastroenterology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEosinophilic esophagitis (EoE) is characterized by high levels of eosinophils in the esophageal mucosa. Patients with the disease present with a range of symptoms, including dysphagia (difficulty swallowing). The aim of this analysis was to assess the psychometric properties of the Dysphagia Symptom Questionnaire (DSQ), a patient-reported outcome (PRO) measure of dysphagia associated with EoE. Psychometric properties of the DSQ were assessed using data collected from a 12-week, phase 2, multicenter, randomized, double-blind, placebo-controlled trial of budesonide oral suspension in adolescents and adults (11-40 years old) with EoE.
resultsThe study population comprised 93 patients with EoE; 94.6% of whom were white, 68.8% were male and the mean age (standard deviation) was 21.6 (7.7) years. Patients had been diagnosed with EoE for a mean of 37.6 months before study initiation. The DSQ was feasible to implement with few item-level data missing at baseline. Item discrimination was high, with floor and ceiling effects below the predefined threshold (≤9%). Higher DSQ scores corresponded with presence and increased severity of dysphagia, indicative of strong item discrimination among patients at baseline (threshold >50%). The DSQ was able to detect changes in symptoms over time and produced similar outcomes to those from physician- and other patient-rated measures, supportive of construct validity. The DSQ had strong test-retest reliability (intraclass correlation coefficient,
conclusionsThese analyses support the DSQ as a valid and reliable measure of dysphagia in patients with EoE. Changes in DSQ scores suggest a level of agreement between clinician, patient and histologic response. The DSQ should therefore be considered a viable PRO measure of dysphagia for use in future therapeutic studies of EoE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.